Equity Profile

APLS

Apellis Pharmaceuticals, Inc.

Health CareBiotechnology$5.3B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will help gauge how well Apellis is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market performance and acceptance of its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

APLS Q2-2026 Earnings Preview

Context

Company Snapshot

Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, Apellis is particularly known for its work in complement biology, which plays a crucial role in the immune system and has implications for various conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+40.64%

Avg Stock Reaction

-4.40%

Last Quarter Recap

In Q1 2026, Apellis reported an EPS of $0.15, significantly beating expectations of -$0.38. However, the stock saw a slight decline of 0.27% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Focus on expanding the market for its lead product.
Commitment to ongoing clinical trials and research.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Apellis's upcoming earnings report, especially after a strong EPS surprise last quarter. However, the lack of revenue guidance raises some concerns.

Bull Case

If Apellis can continue its trend of beating EPS estimates and show strong revenue growth, it could signal robust demand for its products and lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected revenue growth for the upcoming quarter?

Revenue growth will be a critical indicator of market acceptance and the effectiveness of Apellis's sales strategy.

Will there be any updates on ongoing clinical trials?

Updates on clinical trials can significantly impact investor confidence and the company's future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Apellis's potential for revenue growth based on its recent product launches and market expansion efforts.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational performance.

Options pricing suggests a significant move, reflecting heightened investor interest and potential for positive surprises.

Key Risk

If the revenue growth exceeds expectations, it could lead to a re-evaluation of the company's market position.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around Apellis's ability to sustain growth and manage operational challenges in a competitive biotech landscape.

Bull Confirmed If

A revenue growth rate of over 20% compared to the previous quarter would confirm the bull case.

Bear Confirmed If

A revenue decline or stagnation would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±34.35%

Historical Avg

±8.8%

Pricing rich

The options market is pricing in a substantial move, indicating that investors expect significant volatility around the earnings announcement.

Options are pricing ±34.3% while APLS has averaged ±8.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

2.6%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Apellis beats expectations, history suggests a potential stock increase of around 8.79%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 3.80%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific revenue guidance for the upcoming quarter.
2Updates on the status of clinical trials and product launches.
3Management's commentary on market conditions and competitive landscape.
4Insights into operational efficiencies and cost management strategies.
5Any new partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will help gauge how well Apellis is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market performance and acceptance of its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

APLS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+40.64%

Avg Stock Reaction

-4.40%

Last Quarter Recap

In Q1 2026, Apellis reported an EPS of $0.15, significantly beating expectations of -$0.38. However, the stock saw a slight decline of 0.27% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Focus on expanding the market for its lead product.
Commitment to ongoing clinical trials and research.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Apellis's upcoming earnings report, especially after a strong EPS surprise last quarter. However, the lack of revenue guidance raises some concerns.

Bull Case

If Apellis can continue its trend of beating EPS estimates and show strong revenue growth, it could signal robust demand for its products and lead to a positive market reaction.

Bear Case

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected revenue growth for the upcoming quarter?

Revenue growth will be a critical indicator of market acceptance and the effectiveness of Apellis's sales strategy.

Will there be any updates on ongoing clinical trials?

Updates on clinical trials can significantly impact investor confidence and the company's future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Apellis's potential for revenue growth based on its recent product launches and market expansion efforts.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational performance.

Options pricing suggests a significant move, reflecting heightened investor interest and potential for positive surprises.

Key Risk

If the revenue growth exceeds expectations, it could lead to a re-evaluation of the company's market position.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around Apellis's ability to sustain growth and manage operational challenges in a competitive biotech landscape.

Bull Confirmed If

A revenue growth rate of over 20% compared to the previous quarter would confirm the bull case.

Bear Confirmed If

A revenue decline or stagnation would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±34.35%

Historical Avg

±8.8%

Pricing rich

The options market is pricing in a substantial move, indicating that investors expect significant volatility around the earnings announcement.

Options are pricing ±34.3% while APLS has averaged ±8.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

2.6%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Apellis beats expectations, history suggests a potential stock increase of around 8.79%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 3.80%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific revenue guidance for the upcoming quarter.
2Updates on the status of clinical trials and product launches.
3Management's commentary on market conditions and competitive landscape.
4Insights into operational efficiencies and cost management strategies.
5Any new partnerships or collaborations that could enhance growth.